MHRA Updates Guidance on Handling of Approved or Pending DCP and MRP
The new guidance outlines the approach the MHRA intends to take for products approved or pending in a decentralized procedure or mutual recognition procedures.
The Medicines and Healthcare products Regulatory Agency (MHRA) updated its guidance concerning decentralized procedure (DCP) and mutual recognition procedures (MRP) on June 24, 2022. The guidance details how MHRA handles products already approved or pending in ongoing DCPs and MRPS, while the new updates detail how to convert a Great Britain Product Licenses (GBPL) or Northern Ireland (PLNI) license to a UK-wide license.
The update concerning GBPL and PLNI excludes products that are already the subject of an EU Community Marketing authorization in Northern Ireland or those that fall within the mandatory scope of the European Medical Agency’s centralized procedure. A full breakdown of the updated guidelines can be found on the MHRA site.
Source: MHRA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
